Department of Intensive Care Medicine, Hospital Universitari Sant Pau, Barcelona, Spain.
Translational Research Laboratory, Institut d'Investigació i Innovació Parc Taulí I3PT Universitat Autònoma de Barcelona Sabadell, Parc del Tauli- 08208 Sabadell, Barcelona, Spain.
Trials. 2022 Jan 10;23(1):30. doi: 10.1186/s13063-021-05991-2.
It is uncertain whether awake prone positioning can prevent intubation for invasive ventilation in spontaneous breathing critically ill patients with acute hypoxemic respiratory failure. Awake prone positioning could benefit these patients for various reasons, including a reduction in direct harm to lung tissue, and prevention of tracheal intubation-related complications.
The PRONELIFE study is an investigator-initiated, international, multicenter, randomized clinical trial in patients who may need invasive ventilation because of acute hypoxemic respiratory failure. Consecutive patients admitted to participating ICUs are randomly assigned to standard care with awake prone positioning, versus standard care without awake prone positioning. The primary endpoint is a composite of tracheal intubation and all-cause mortality in the first 14 days after enrolment. Secondary endpoints include time to tracheal intubation and effects of awake prone positioning on oxygenation parameters, dyspnea sensation, and complications. Other endpoints are the number of days free from ventilation and alive at 28 days, total duration of use of noninvasive respiratory support, total duration of invasive ventilation, length of stay in ICU and hospital, and mortality in ICU and hospital, and at 28, 60, and 90 days. We will also collect data regarding the tolerance of prone positioning.
The PRONELIFE study is among the first randomized clinical trials investigating the effect of awake prone positioning on intubation rate in ICU patients with acute hypoxemic failure from any cause. The PRONELIFE study is sufficiently sized to determine the effect of awake prone positioning on intubation for invasive ventilation-patients are eligible in case of acute hypoxemic respiratory failure without restrictions regarding etiology. The PRONELIFE study is a pragmatic trial in which blinding is impossible-however, as around 35 ICUs worldwide will participate in this study, its findings will be highly generalizable. The findings of the PRONELIFE study have the potential to change clinical management of patients who may need invasive ventilation because of acute hypoxemic respiratory failure.
ISRCTN ISRCTN11536318 . Registered on 17 September 2021. The PRONELIFE study is registered at clinicaltrials.gov with reference number NCT04142736 (October, 2019).
清醒俯卧位是否可以预防因急性低氧性呼吸衰竭而进行有创通气的自主呼吸危重症患者的插管,目前尚不确定。清醒俯卧位可能会通过多种原因使这些患者受益,包括减少对肺组织的直接损害,以及预防与气管插管相关的并发症。
PRONELIFE 研究是一项由研究者发起的、国际、多中心、随机临床试验,纳入可能因急性低氧性呼吸衰竭而需要有创通气的患者。连续入组的 ICU 患者被随机分配到标准治疗加清醒俯卧位组,或标准治疗不加清醒俯卧位组。主要终点是纳入后 14 天内气管插管和全因死亡率的复合终点。次要终点包括气管插管时间和清醒俯卧位对氧合参数、呼吸困难感觉和并发症的影响。其他终点包括无通气天数和 28 天存活天数、无创呼吸支持总使用时间、有创通气总使用时间、ICU 和医院住院时间、ICU 和医院死亡率以及 28、60 和 90 天时的死亡率,我们还将收集俯卧位耐受情况的数据。
PRONELIFE 研究是第一项随机临床试验,旨在研究清醒俯卧位对任何原因导致急性低氧性衰竭的 ICU 患者插管率的影响。PRONELIFE 研究的规模足以确定清醒俯卧位对有创通气插管的影响——患者符合急性低氧性呼吸衰竭的纳入标准,无病因限制。PRONELIFE 研究是一项实用性试验,无法设盲——然而,由于全球约有 35 家 ICU 参与这项研究,其结果将具有高度的普遍性。PRONELIFE 研究的结果有可能改变可能因急性低氧性呼吸衰竭而需要有创通气的患者的临床管理。
ISRCTN,ISRCTN85661622。于 2021 年 9 月 17 日注册。PRONELIFE 研究在 clinicaltrials.gov 上注册,注册号为 NCT04142736(2019 年 10 月)。